Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer
Keywords: بیماری پیشرفته; HER; human epidermal growth factor receptor; NSCLC; non-small cell lung cancer; DLT; dose-limiting toxicity; MTD; maximum tolerated dose; EGFR-TKI; epidermal growth factor receptor-tyrosine kinase inhibitor; RECIST; response evaluation criteria in solid t